Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) passed China's medical products administrator's generic drug quality and efficacy consistency evaluation for nadroparin calcium injection.
The drug is used to prevent and treat thrombosis and related cardiovascular conditions, according to a filing made on Friday with the Shanghai Stock Exchange.
Shares of the pharmaceutical company closed 2% higher Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments